Abstract: The present invention provides a formulation of Coenzyme Q10 that can be re-dispersed from a stable dry powder to formulation to yield a nanodispersion that can be readily aerosolized for inhalation.

Abstract: Disclosed herein is a single step catalytic process for the production of enantiomerically pure ?-Aryloxy-??-Azido/Alkoxy alcohols of formula (A). The invention, in particular discloses phenolytic kinetic resolution of racemic anti and syn azido/alkoxy epoxides to generate two stereocentres of high optical purities of formula (A).

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 2-(3-hydroxy-3-methyl-butyl)-6-(het)aryl-p-quinone or as 2-(3-hydroxy-3-methylbutyl)-3-(het)aryl-p-quinone derivatives. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

Abstract: Described herein is a degradable linking agent of formula Photo1-LG-Photo2, wherein Photo1 and Photo2 independently represent at least one photoreactive group and LG represents a linking group comprising one or more silicon atoms or one or more phosphorous atoms. The degradable linking agent includes a covalent linkage between at least one photoreactive group and the linking group, wherein the covalent linkage between at least one photoreactive group and the linking group is interrupted by at least one heteroatom. A method for coating a support surface with the degradable linking agent, coated support surfaces and medical devices are also described.

Abstract: Substituted phenacyl molecules are provided and employed to create molecules and polymers/copolymers that exhibit photoresponsiveness. In some instances, the substituted phenacyl molecule is incorporated into the polymer/copolymer backbone, and photoirradiation of the polymer/copolymer causes the substituted phenacyl group to break down and the polymer/copolymer to undergo degradation. In other instances, the substituted phenacyl molecules extend as a side chain from the polymer/copolymer backbone. In yet other instances the substituted phenacyl molecules extend as a side chain from the polymer/copolymer backbone, and a drug or polymer additive is linked to the photoresponsive substituted phenacyl group such that photoirradiation releases the drug or additive. In yet other embodiments the substituted phenacyl molecules extend as a side chain from the polymer/copolymer backbone, and serve to link the polymer/copolymer to another polymer/copolymer backbone, and photoirradiation breaks the links.

Abstract: The present application relates to a method for inducing germination of a spore forming bacterium, specifically, a method for inducing germination of a spore forming bacterium, comprising: using one or more compounds having a phenolic backbone to induce germination of a spore forming bacterium selected from the group consisting of the genus Bacillus, the genus Geobacillus, and the genus Aeribacillus; to a germination inducer for a spore forming bacterium; and to a kit for use in germination of a spore forming bacterium.

Abstract: The present invention relates to phenylalkyl-substituted 2-[2-chloro-4-(4-chloro-phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds of formula I as defined in the description, and the N-oxides, and salts thereof, their preparation and intermediates for preparing them. The invention also relates to the use of these compounds for combating harmful fungi and seed coated with at least one such compound and also to compositions comprising at least one such compound.

Abstract: A compound of formula (I) wherein Rf is —CF3, —C2F5, or —CF2CFXCF3; X is —F, or —OC3F7; Y is —H, —Cl, or —Br; R is —OH, —(CH2)nOH, —(OCH2CH2)mOH, —(CH2)n(OCH2CH2)mOH, —O—C(O)—R1, —(CH2)nO—C(O)R1, —(OCH2CH2)mOC(O)—R1, —C(O)NHw(CH2CH2OH)2-w, —C?N, —C?CH, or —C(O)R2; n is 1 to 10; m is 1 to 10; R1 is C1 to C10 alkyl; R2 is —H, C1 to C10 alkyl, —Cl, or —OCH2CH2OH; a is 1 to 5; b is 1 to 5; and w is 0, 1 or 2.

Abstract: Disclosed are certain compounds according to the general formula (I) and their use as flavoring and fragrancing compounds, as well as fragranced and flavored compositions comprising the compounds of formula (I), and methods for providing a flavor or fragrance to compositions and articles utilizing the compounds of formula (I).

Abstract: The present invention concerns a pharmaceutical composition comprising a compound of formula A being (2,3(dihydroxy), 5[3(1,2)butadiene], 1(3hydroxy,3methyl,4pentene)benzene) and/or a compound of formula B being (2,3(dihydroxy), 5[3(1,2)butadiene], 2[2methylbutane]benzenal) and/or a compound of formula C being (2,3(dihydroxy), 5[3(1,2)butadiene], 2hydroxy,3butene benzoate) or a combination thereof for use as a medicament or for in vivo use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses.

Abstract: There is provided a process for the preparation of a compound of formula (I), wherein R1, R2, R3, R4, X and Y are as described in the description. Such compounds may, for example, be useful intermediates in the synthesis of drugs such as Dronedarone.

Abstract: To provide a liquid crystal compound having a large negative value of dielectric anisotropy (??). A compound is represented by formula (1): wherein, in formula (1), R1 and R2 are hydrogen, halogen or alkyl having 1 to 10 carbons, and in the alkyl, at least one of —CH2— may be replaced by —O—, at least one of —(CH2)2— may be replaced by —CH?CH—, and at least one of hydrogen may be replaced by halogen; ring A1 and ring A2 are 1,4-cyclohexylene or 1,4-phenylene; Z1 is a single bond, —(CH2)2—, —CH2O—, —OCH2—, —CF2O—, —OCF2—, —COO—, or —OCO—; Y is halogen, —CF3, —CF2H or —CH2F; and m, n and p are 0, 1 or 2, and a sum (m+n) of m and n is 0, 1 or 2.

Abstract: What is described are 3-aminocarbonyl-substituted benzoylcyclohexanediones of the formula (I) as herbicides. In this formula (I), R1 to R5 are radicals such as hydrogen, organic radicals such as alkyl, and other radicals such as halogen. X is alkylene.

Abstract: The present invention describes phytochemicals present in maple syrup and maple tree extracts by butanol, ethyl acetate and methanol. Novel compounds are isolated from maple syrups, including one compound Quebecol generated in the maple syrup manufacturing process. Also described are digesting extract of maple syrup. The phytochemicals may be used for the treatment or prevention of cancers, metabolic syndromes, diabetes, microorganism infections and/or antioxidants.

Abstract: A formulation comprising an ophthalmically effective amount of one or more quinones of Formula I. Use of a formulation comprising one or more quinones of Formula I for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are associated with a neurodegenerative or trauma disorder is also discussed. A method of treating or controlling the ocular symptoms associated with neurodegenerative diseases or trauma with a formulation comprising one or more quinones of Formula I is also discussed. A method of treating or controlling the ocular symptoms associated with mitochondrial myopathies with a formulation comprising one or more quinones of Formula I is also discussed.

Abstract: Method of identifying and using compounds which inhibit the expression or activity of micro-RNAs for preventing and/or attenuating ageing, and/or for hydrating skin. An in vitro method for screening for candidate compounds for preventing and/or attenuating ageing of the skin, and/or for hydrating the skin, includes the following steps: a. bringing at least one test compound in contact with a sample of keratinocytes; b. measuring the expression or the activity of at least one microRNA in the keratinocytes; c. selecting the compounds for which an inhibition of at least 20%, preferably at least 30%, preferably at least 40% of the expression or an inhibition of at least 20%, preferably at least 30%, preferably at least 40% of the activity of at least one microRNA is measured in the keratinocytes treated in a. compared with the untreated keratinocytes.

Abstract: There is provided a process for the preparation of a compound of formula (III), wherein X and Y are as described in the description. Such compounds may, for example, be useful intermediates in the synthesis of drugs such as Dronedarone. There is also provided a process for the preparation of a compound of formula (I).

Abstract: Embodiments of the present invention provide compounds (such as Formula (I) compounds, Formula (II) compounds, and various embodiments thereof). Compositions comprising those compounds are also provided. Methods for their preparation are included. Also, uses of the compounds are included, such as administering and treating diseases (e.g., cancer and infections).

Abstract: The invention relates to a novel mediator used in the production of wood composite materials that are devoid of binding agents.

Abstract: A process for the preparation of an alkali metal salt of 4-chloro-4?-hydroxy benzophenone including the steps of (a) preparing purified 4-chloro-4?-hydroxy benzophenone by a process including distilling under reduced pressure a liquid containing 4-chloro-4?-hydroxy benzophenone and a solvent selected from diphenyl sulphone, diphenylene sulphone, benzophenone and dichlorobenzophenone, and then (b) preparing the alkali metal salt of thus purified 4-chloro-4?-hydroxy benzophenone by the reaction of the purified 4-chloro-4?-hydroxy benzophenone with a stoichiometric excess of at least one alkali metal base. There is also described a polymerization process using the alkali metal salt to yield PEK with high inherent viscosity and improved mechanical and thermal properties.

Abstract: There is provided a process for the preparation of a compound of formula (I), wherein R1, R2, R3, R4, X and Y are as described in the description. Such compounds may, for example, be useful intermediates in the synthesis of drugs such as Dronedarone. Intermediate steps of the process comprise formulae according to (II) and (III).

Abstract: This invention discloses the method for preparing desmosdumotin C, the series of desmosdumotin C derivatives and their manufactures, and the total synthesis of desmosdumotin B. The invention also discloses uses of the derivatives and pharmaceutical compositions containing the same in preparation of medicines for treatment of tumor or AIDS.

Abstract: The instant invention relates to new photolatent compounds of the formula I wherein R1 and R2 are each independently of the other C1-C10alkyl or C3-C8cycloalkyl, R3 is hydrogen or C1-C4alkyl, and wherein the photochemically cleaved group R4OH is selected from the group consisting of fragrances, UV absorbers, anti-microbials, anti-fogging agents and clarifiers; with the proviso that, when R1 and R2 are tert-butyl and R3 is hydrogen, R4 is not methyl or phenyl.

Abstract: Trisubstituted phenol compounds and methods of using the compounds, e.g., for anesthetizing a subject, are disclosed.

Abstract: A photoinitiator compound is functionalized with alkoxy groups so as to be soluble in alkoxy-containing monomers. The photoinitiator has a formula of R1—(OR2)n—OC(?O)—R3, wherein R1—(OR2)n— represents an alkoxy group and R3 represents a photoinitiator structure. The photoinitiator may be used in a composition for incorporation into inks.

Abstract: It is intended to provide compositions and foods for use in the treatment, prophylaxis, or amelioration of diseases or symptoms which can be treated, prevented or ameliorated by activating PPAR, in particular, insulin resistant diabetes and hyperlipidemia. Namely, medicinal compositions usable in treating, preventing or improving diseases or symptoms which can be treated, prevented or ameliorated by activation PPAR which contain humulones, isohumulones or lupulones or pharmaceutically acceptable salts or solvates thereof.

Abstract: A halogenated bisdiarylaminopolycyclic aromatic compound, polymers made therefrom, and polymeric light emitting diode devices using the polymers are described. The halogenated compound is represented by formula (I), wherein Ar and Ar? are each independently substituted or unsubstituted aryl groups and Z is a polycyclic arylene group, wherein at least one of the Ar? groups is a haloaryl group. Devices using polymers prepared from the halogenated compound exhibit improved performance and longer lifetime, presumably as a result of the presence of the geometrically constrained diarylaminopolycyclic aromatic groups in the polymer backbone.

Abstract: Disclosed are methods, compounds, and compositions related to the production of coenzyme Q.

Abstract: This invention relates to an immunoadjuvant, which has an excellent antibody production enhancing function and is highly safe, and a vaccine composition comprising the immunoadjuvant.

Abstract: This invention discloses the method for preparing desmosdumotin C, the series of desmosdumotin C derivatives and their manufactures, and the total synthesis of desmosdumotin B. The invention also discloses uses of the derivatives and pharmaceutical compositions containing the same in preparation of medicines for treatment of tumor or AIDS.

Abstract: The present invention relates to substituted hydroxyacetophenone derivatives having antiproliferative and antimicrobial properties, to pharmaceutical compositions containing them, as well as to a method of preparing them. Moreover, the hydroxyacetophenone derivatives according to the invention can serve as organic intermediates for the preparation of biologically active compounds.

Abstract: The present invention relates to a novel polymorphic form of atovaquone. More particularly, it relates to a novel crystalline form, that has improved solubility and other bulk characteristics suitable for pharmaceutical application. The present invention also relates to processes for preparing a new polymorphic form of atovaquone and its use in industry.

Abstract: Pyrocatechin derivatives of formula I wherein R illustrates a group of formulae Ia, Ib, Ic or Id R1 is 4-halogen-but-2-enyl, R2 is lower alkyl or cycloalkyl, R3 is lower alkoxy and R4 is lower alkoxy lower alkoxy, or, where R is a group of formula (Ia), it is hydroxy, hydroxy lower alkoxy or a group of formula Ie R5 is reactive esterified hydroxy, R6 is azido and R7 is lower alkyl, lower alkenyl, cycloalkyl or aryl lower alkyl, and their salts, are valuable intermediates in the production of active ingredients for medicaments.

Abstract: The present invention provides a convergent method for the synthesis of ubiquinones and ubiquinone analogues. Also provided are precursors of ubiquinones and their analogues that are useful in the methods of the invention. The invention further provides an improved method for the carboalumination of alkyne substrates.

Abstract: This application is concerned with the controlled nucleation of solutes (i.e. dissolved solids) from solution. It has been found that the energy barrier for dissolved solids to nucleate is affected by the surface charge density of the reaction vessel (and hence the mass-to-charge ratio of vessel). The reaction vessel may, for example, comprise a levitated droplet of the solution having an “excess net charge”. That is, ions present in the vessel of a single polarity are in excess of the counterions of opposite polarity. An increase in the surface charge density of the vessel (and hence a reduction in the mass-to-charge ratio of the vessel) causes the barrier for nucleation to decrease. These findings can be exploited using instruments commonly used in wall-less sample preparation to elicit selective control over the induction of nucleation and subsequent crystallization of target solutes of interest in the condensed phase.

Abstract: The invention relates to the use of idebenone for the preparation of a topically-applied composition which is intended to inhibit melanogenesis, to reduce cutaneous coloration or to brighten same and/or produce cutaneous depigmentation. More specifically, the invention relates to a topically-applied composition comprising a cosmetic, pharmaceutical and/or dermatologically-effective amount of idebenone, derivatives thereof or mixtures of same, in which there is an effective amount of idebenone or the derivative thereof such as to produce cutaneous depigmentation.

Abstract: Bioavailability of Coenzyme-Q 10 (“Co-Q10”), an oil-soluble substance, can be enhanced in a subject by modifying, e.g. nanonizing or charging, the form of Co-Q10. Co-Q10 bioavailability also can be enhanced by administering Co-Q10 to the subject as an oil (lipid)-based and water (hydro)-based mixed composition, along with other optional components, such as oils, resins and other carriers. Accordingly, the invention provides various Co-Q10 compositions, e.g. compositions comprised of (i) Co-Q10 dissolved in one or more Co-Q10-soluble oils and (ii) Co-Q10 in admixture with at least one water-dispersible agent. A Co-Q10 complex of the invention, therefore, yields an increased cell absorption rate, as well as an enhanced percentage of Co-Q10 peak absorption, compared to previously known compounds. Methods for making and using the aforementioned compositions also are provided.

Abstract: The present invention is refereed to a white solid photoinitiator in the form of powder and consisting of 2-hydroxy-1-{4-[4-(2-hydroxy-2-methyl-propionyl)-phenoxy]-phenyl}-2-methyl-propan-1-one (COMPOUND1), and to the procedure for its preparation.

Abstract: A water-free composition for the bleaching and brightening of human hair at the same time with a simultaneous conditioning effect is disclosed. The particularly exceptional effects of the bleaching agent is that improvement of shine and elasticity. The bleaching agent comprises a) at least one compound with a bleaching or brightening effect, in particular a peroxide and/or an ammonium salt, and b) 0.001% to 10% by weight, calculated to the total composition, of at least one ubiquinone of the formula (I) wherein n is a number from 1 to 10, and at least one sphingolipid of the formula II where R1 and R2 are independent from each other alkyl- or alkenyl group mit 10 to 22 carbon atoms, R3 is methyl, ethyl, n-propyl or isopropyl group and n is a number between 1 to 6, preferably 2 or 3.

Abstract: The present invention pertains to compounds of the following formula: (1) wherein: RALK is primary or secondary aliphatic saturated C2-6alkyl; each of RB2, RB3, RB4, and RB5 is independently —H, —OH, or —OMe; each of R1 and R2 is independently: —H, optionally substituted C1-4alkyl, or optionally substituted C5-20aryl; RA3 is —H, —OH, —OC(?O)RE, —OS(?O)2OH, or —OP(?O)(OH)2; RE is: —H, optionally substituted C1-6alkyl, optionally substituted C3-20heterocyclyl, or optionally substituted C5-20aryl; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof.

Abstract: The present invention provides a new fluorine-containing acetophenone derivative useful as a photo initiator, and a surface layer material containing the fluorine-containing acetophenone derivative. The present invention provides inexpensively an article with a hard coat excellent in anti-staining property, lubricity, scratch resistance and abrasion resistance, and provides a method for forming the hard coat. A fluorine-containing acetophenone derivative represented by the following general formula (I): wherein R1, R2 and R3 each independently represent an organic group other than aryl group, a hydrogen atom, a halogen atom or a hydroxyl group, provided that the following case does not take place: all of R1, R2 and R3 are simultaneously hydrogen atoms; and any two of R1, R2 and R3 may be linked to each other to form a ring, and R4 represents a fluorine-containing organic group.

Abstract: A compound of formula wherein Y represents a pyridyl group, or a phenyl group of formula wherein R3 represents a hydrogen atom, a CF3 group or an alkoxy group, R4 represents a hydrogen atom, an alkyl group, or a CF3 group, R5 represents a hydrogen atom, an alkyl group, a CF3 group or an alkoxy group, and R1 and R2 are the substituents of a terminal alkene of formula wherein R1 represents an alkyl or alkylene group, a mono- or poly-cycloalkyl group, or a phenyl group that optionally includes one or several hetero-atoms of oxygen, nitrogen, phosphorous or sulfur; R2 represents a hydrogen atom, an alkyl or alkylene group, a mono- or poly-cycloalkyl group, or a phenyl group that optionally includes one or several hetero-atoms of oxygen, nitrogen, phosphorous and sulfur.

Abstract: The present invention provides a fragrance precursor of formula I: that is capable of forming a fragrant ketone of formula II: and a fragrant lactone of formula III:

Abstract: What is described are derivatives of benzoylcyclohexanediones of the formula (I) and their use as herbicides. In this formula (I), R1a, R1b, R1c, R2, R3, R4 and R5 denote various radicals, X1 is a bridging atom, X2 is a carbon chain and X3 is a chalcogen atom or an oximino radical.

Abstract: The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into the nucleus of a cell. The invention encompasses methods of use of such compounds for treatment or prevention of infectious diseases, such as parasitic and viral diseases, including, for example, malaria and acquired immunodeficiency syndrome. The use of the compounds to detect certain specific protein structures which are present in nuclear localization sequences is also taught.

Abstract: The invention describes a process for the preparation of 1,2-diarylethanones by reaction of an arylacetonitrile and an aromatic compound and hydrolysis of the ketimine compound formed, where the solvent used for the reaction is at least one dialkyl ether of a mono- or polyalkylene glycol or a cyclic ether having at least two oxygen atoms. The process produces good yields at room temperature, and drying of the solvent is not required.

Abstract: A process is specified by which the xanthohumol present in hops can be isolated in high yield in an economical manner. In the process an ethanol pure resin extract is first extracted with a liquid or supercritical solvent in which the xanthohumol is insoluble and the resultant extraction residue is first washed with a first solvent mixture and then the extraction residue which has been washed with the first solvent mixture is, after removing the first solvent mixture, extracted with a second solvent mixture, the first solvent mixture having a higher polarity than the second solvent mixture. The hop extract produced from the second solvent mixture has a xanthohumol content of at least 85% by weight.

Abstract: An oxygen scavenging composition or system is provided comprising an oxygen scavenging material, a photoinitiator, and at least one catalyst effective in catalyzing an oxygen scavenging reaction, wherein the photoinitiator comprises a benzophenone derivative containing at least two benzophenone moieties. A film, a multi-phase composition, a multi-layer composition, a multi-layer film, an article comprising the oxygen scavenging composition, a method for preparing the oxygen scavenging composition, and a method for scavenging oxygen are also provided. Non-extractable benzophenone derivative photoinitiators and methods for preparing same are also provided.

Abstract: An antimicrobial compound, composition containing such compound, and method of use of the same for reducing the presence of microorganism on a substrate or in a fluid environment comprising an antimicrobial effective carrier and one or more essential antimicrobial compounds including non-halogenated naphthol compounds.

Abstract: An improved method is described for making 9-deoxy-PGF1-type compounds. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds. “Also described are novel intermediate compounds used in the process described for making 9-deoxy-PGF1-type compounds.